A Study of Lipid Profile in Chronic Kidney Disease Patients

被引:0
|
作者
Rizwan, Muhammad [1 ]
Lodhi, Muhammad Taha [1 ]
Maqsood, Asim [2 ]
Sayed, Tahir Mukhtar [3 ]
机构
[1] Shaikh Zayed Hosp, Lahore, Pakistan
[2] Avicenna Med Coll & Hosp, Med, Lahore, Pakistan
[3] Fauji Med Coll, Med, Rawalpindi, Pakistan
来源
关键词
Chronic Kidney Disease; Lipid Profile; Lipid Profile Abnormalities; FATTY LIVER; PCSK9;
D O I
10.53350/pjmhs211593087
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Aim: Chronic kidney disease patients are more likely to develop cardiovascular diseases caused by atherosclerosis accelerated rate and variety of other factors, of which they exhibit the abnormality of lipid profile atherogonic characteristics. The current study aim was to investigate the lipid profile abnormalities pattern in non-diabetic chronic kidney disease patients and to evaluate the association between the lipid profile alteration extent and renal impairment degree. Methods: This cross-sectional study was carried out on 118 chronic disease patients in the Department of Nephrology, Shaikh Zayed Hospital Lahore during the period, from August 2020 to May 2021. All the patients were carefully chosen based on their eligibility criteria. A history was taken, clinical investigation was performed, and biochemical tests were conducted. Blood was drawn for lipid profile analysis after 9 hours abstaining. The Institutional Ethical Committee approved the study and informed consent was taken from each individual. Chronic Kidney Disease as defined by the KDOQI Criteria Kidney damage for three months, defined as functional kidney abnormalities with or without decreased GFR, manifested by either: Pathological abnormalities; kidney damage markers such as changes in blood or urine composition, or abnormalities in imaging tests. GFR of less than 60 mL/min/1.73m(2) for 3 months, with or without kidney damage. SPSS version 20 was used for data analysis. Results: The study included 118 patients, 79 (66.9%) of whom were males and 39 (33.1%) were females. The mean age of patients was 49.46 + 9.35 years with an age range of 28 to 78 years. Stage 5CKD patients were 23 who underwent dialysis. Chronic kidney disease patients had lower HDL and higher levels of triglyceride whereas, with chronic kidney disease stage progression, the HDL and TGL levels increased. In both stages 4 and 5 CKD, there is a positive correlation between triglyceride levels and serum phosphorous and TGL and calcium had inverse correlation. Dialysis patients' lipid profiles do not differ from those of non-dialysis patients. Conclusion: Our study found that patients with non-diabetic CKD have high triglyceride levels, low HDL, and had LDL and total cholesterol unchanged levels. As the CKD stage advances and GFR declines, triglyceride increases, and HDL decreases. TGL and serum phosphorous had a positive association in chronic kidney disease stage 4 and 5 whereas TGL and serum calcium had an inverse correlation in stages 4 and 5. Moreover, no significant difference between dialysed and non-dialysed chronic kidney disease patients' lipid profiles was observed.
引用
收藏
页码:3087 / 3090
页数:4
相关论文
共 50 条
  • [21] THE "LIPID ACCUMULATION PRODUCT" IN OLDER PATIENTS WITH CHRONIC KIDNEY DISEASE
    Efremova, E.
    Shutov, A.
    ATHEROSCLEROSIS, 2021, 331 : E236 - E236
  • [22] Lipid and nutritional profiles of Caribbean patients with chronic kidney disease
    Idris, Saleh
    AFRICAN HEALTH SCIENCES, 2023, 23 (03) : 645 - 654
  • [23] Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease
    Roy O. Mathew
    Robert S. Rosenson
    Radmila Lyubarova
    Rafia Chaudhry
    Salvatore P. Costa
    Sripal Bangalore
    Mandeep S. Sidhu
    Cardiovascular Drugs and Therapy, 2021, 35 : 479 - 489
  • [24] Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease
    Mathew, Roy O.
    Rosenson, Robert S.
    Lyubarova, Radmila
    Chaudhry, Rafia
    Costa, Salvatore P.
    Bangalore, Sripal
    Sidhu, Mandeep S.
    CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (03) : 479 - 489
  • [25] Lipid monitoring in patients with diabetes and chronic kidney disease.
    Guo, HF
    Gilbertson, DT
    Collins, AJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 503A - 504A
  • [26] Author Correction: Lipid management in patients with chronic kidney disease
    Charles J. Ferro
    Patrick B. Mark
    Mehmet Kanbay
    Pantelis Sarafidis
    Gunnar H. Heine
    Patrick Rossignol
    Ziad A. Massy
    Francesca Mallamaci
    Jose M. Valdivielso
    Jolanta Malyszko
    Marianne C. Verhaar
    Robert Ekart
    Raymond Vanholder
    Gerard London
    Alberto Ortiz
    Carmine Zoccali
    Nature Reviews Nephrology, 2019, 15 : 121 - 121
  • [27] Lipid-lowering therapy in patients with chronic kidney disease
    Walker, R
    NEPHROLOGY, 2005, 10 : S231 - S234
  • [28] Clinical profile of Uremic polyneuropathy in Chronic Kidney Disease patients
    Aradhey, Parag
    Bakre, Anand
    Kumar, Sunil
    Acharya, Sourya
    MEDICAL SCIENCE, 2020, 24 (102) : 945 - 951
  • [29] COAGULATION PROFILE IN PATIENTS WITH CHRONIC KIDNEY DISEASE BEFORE AND AFTER KIDNEY TRANSPLANTATION
    Kim, Ji Il
    Cho, Jinbeom
    Kim, Mihyung
    TRANSPLANT INTERNATIONAL, 2017, 30 : 98 - 98
  • [30] Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials
    Nikolic, Dragana
    Nikfar, Shekoufeh
    Salari, Pooneh
    Rizzo, Manfredi
    Ray, Kausik K.
    Pencina, Michael J.
    Mikhailidis, Dimitri P.
    Toth, Peter P.
    Nicholls, Stephen J.
    Rysz, Jacek
    Abdollahi, Mohammad
    Banach, Maciej
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (05) : 435 - 451